Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NUVB |
---|---|---|
09:32 ET | 23442 | 2.43 |
09:34 ET | 45993 | 2.4102 |
09:36 ET | 21206 | 2.395 |
09:38 ET | 4660 | 2.36 |
09:39 ET | 10366 | 2.355 |
09:41 ET | 2207 | 2.35 |
09:43 ET | 19561 | 2.355 |
09:45 ET | 8370 | 2.365 |
09:48 ET | 1816 | 2.38 |
09:50 ET | 13797 | 2.375 |
09:52 ET | 4533 | 2.375 |
09:54 ET | 15117 | 2.425 |
09:56 ET | 6391 | 2.415 |
09:57 ET | 2400 | 2.415 |
09:59 ET | 14680 | 2.41 |
10:01 ET | 7712 | 2.46 |
10:03 ET | 5188 | 2.445 |
10:06 ET | 6100 | 2.445 |
10:08 ET | 4571 | 2.465 |
10:10 ET | 2925 | 2.465 |
10:12 ET | 5985 | 2.445 |
10:14 ET | 4500 | 2.445 |
10:15 ET | 3074 | 2.43 |
10:17 ET | 3274 | 2.4399 |
10:19 ET | 789 | 2.435 |
10:21 ET | 300 | 2.435 |
10:24 ET | 100 | 2.435 |
10:26 ET | 2623 | 2.43 |
10:28 ET | 700 | 2.435 |
10:30 ET | 8225 | 2.435 |
10:32 ET | 600 | 2.43 |
10:33 ET | 1497 | 2.43 |
10:35 ET | 9214 | 2.445 |
10:37 ET | 1690 | 2.435 |
10:39 ET | 804 | 2.435 |
10:42 ET | 4932 | 2.425 |
10:44 ET | 6292 | 2.435 |
10:46 ET | 2189 | 2.4354 |
10:48 ET | 5771 | 2.435 |
10:50 ET | 2195 | 2.435 |
10:51 ET | 773 | 2.43 |
10:53 ET | 2100 | 2.4385 |
10:55 ET | 130834 | 2.415 |
10:57 ET | 3936 | 2.405 |
11:00 ET | 2500 | 2.405 |
11:02 ET | 2600 | 2.405 |
11:04 ET | 1300 | 2.405 |
11:06 ET | 4249 | 2.4 |
11:08 ET | 119044 | 2.405 |
11:09 ET | 128327 | 2.455 |
11:11 ET | 16676 | 2.465 |
11:13 ET | 10758 | 2.47 |
11:15 ET | 2807 | 2.465 |
11:18 ET | 10090 | 2.475 |
11:20 ET | 17712 | 2.475 |
11:22 ET | 8733 | 2.475 |
11:24 ET | 21823 | 2.485 |
11:26 ET | 700 | 2.485 |
11:27 ET | 6285 | 2.475 |
11:29 ET | 100 | 2.475 |
11:31 ET | 1184 | 2.47 |
11:33 ET | 8324 | 2.46 |
11:36 ET | 500 | 2.46 |
11:38 ET | 1463 | 2.46 |
11:40 ET | 4800 | 2.45 |
11:42 ET | 1505 | 2.4508 |
11:44 ET | 300 | 2.45 |
11:45 ET | 9883 | 2.455 |
11:47 ET | 1693 | 2.475 |
11:49 ET | 1204 | 2.475 |
11:51 ET | 425 | 2.475 |
11:54 ET | 2800 | 2.475 |
11:56 ET | 7511 | 2.485 |
11:58 ET | 1010 | 2.485 |
12:00 ET | 708 | 2.485 |
12:03 ET | 5732 | 2.475 |
12:05 ET | 3743 | 2.475 |
12:07 ET | 3885 | 2.49 |
12:09 ET | 35269 | 2.505 |
12:12 ET | 4540 | 2.5 |
12:14 ET | 3335 | 2.49 |
12:16 ET | 200 | 2.48 |
12:18 ET | 4092 | 2.47 |
12:20 ET | 3312 | 2.475 |
12:21 ET | 2370 | 2.475 |
12:23 ET | 3662 | 2.465 |
12:25 ET | 499 | 2.46 |
12:27 ET | 1110 | 2.465 |
12:30 ET | 483 | 2.465 |
12:32 ET | 446 | 2.46 |
12:34 ET | 100 | 2.46 |
12:36 ET | 1100 | 2.4672 |
12:39 ET | 677 | 2.47 |
12:41 ET | 9282 | 2.46 |
12:43 ET | 4800 | 2.465 |
12:45 ET | 6628 | 2.465 |
12:48 ET | 404 | 2.465 |
12:50 ET | 500 | 2.465 |
12:54 ET | 200 | 2.465 |
12:56 ET | 2898 | 2.455 |
12:57 ET | 120 | 2.4579 |
12:59 ET | 400 | 2.45 |
01:01 ET | 100 | 2.455 |
01:03 ET | 13645 | 2.445 |
01:06 ET | 900 | 2.445 |
01:08 ET | 4795 | 2.445 |
01:10 ET | 2511 | 2.445 |
01:12 ET | 1500 | 2.445 |
01:14 ET | 900 | 2.44 |
01:15 ET | 1777 | 2.44 |
01:17 ET | 1200 | 2.435 |
01:19 ET | 6900 | 2.435 |
01:21 ET | 2344 | 2.42 |
01:24 ET | 3027 | 2.425 |
01:26 ET | 4118 | 2.425 |
01:28 ET | 991 | 2.425 |
01:30 ET | 600 | 2.425 |
01:32 ET | 10678 | 2.435 |
01:33 ET | 3725 | 2.435 |
01:35 ET | 235 | 2.435 |
01:39 ET | 200 | 2.43 |
01:42 ET | 3494 | 2.43 |
01:44 ET | 1585 | 2.425 |
01:46 ET | 512 | 2.425 |
01:50 ET | 6431 | 2.425 |
01:51 ET | 100 | 2.425 |
01:53 ET | 200 | 2.425 |
01:55 ET | 600 | 2.42 |
01:57 ET | 100 | 2.42 |
02:00 ET | 298 | 2.42 |
02:02 ET | 850 | 2.42 |
02:04 ET | 1000 | 2.42 |
02:06 ET | 600 | 2.42 |
02:08 ET | 17249 | 2.415 |
02:09 ET | 6122 | 2.415 |
02:11 ET | 400 | 2.415 |
02:13 ET | 940 | 2.41 |
02:15 ET | 2097 | 2.415 |
02:18 ET | 300 | 2.415 |
02:20 ET | 100 | 2.415 |
02:22 ET | 484 | 2.415 |
02:24 ET | 428 | 2.415 |
02:26 ET | 100 | 2.41 |
02:27 ET | 100 | 2.41 |
02:29 ET | 300 | 2.41 |
02:31 ET | 1000 | 2.415 |
02:33 ET | 1531 | 2.415 |
02:36 ET | 3068 | 2.415 |
02:38 ET | 3775 | 2.415 |
02:40 ET | 35868 | 2.415 |
02:42 ET | 900 | 2.415 |
02:44 ET | 3075 | 2.415 |
02:45 ET | 4202 | 2.415 |
02:47 ET | 527 | 2.415 |
02:49 ET | 1143 | 2.415 |
02:51 ET | 1100 | 2.415 |
02:54 ET | 100 | 2.415 |
02:56 ET | 11592 | 2.415 |
02:58 ET | 20481 | 2.425 |
03:00 ET | 818 | 2.425 |
03:02 ET | 910 | 2.425 |
03:03 ET | 800 | 2.425 |
03:05 ET | 1711 | 2.425 |
03:07 ET | 6694 | 2.425 |
03:09 ET | 26449 | 2.445 |
03:12 ET | 912 | 2.445 |
03:14 ET | 1280 | 2.445 |
03:16 ET | 1560 | 2.445 |
03:18 ET | 2644 | 2.445 |
03:20 ET | 26270 | 2.435 |
03:21 ET | 5960 | 2.435 |
03:23 ET | 10575 | 2.445 |
03:25 ET | 4117 | 2.445 |
03:27 ET | 1889 | 2.445 |
03:30 ET | 1339 | 2.445 |
03:32 ET | 2615 | 2.445 |
03:34 ET | 2649 | 2.445 |
03:36 ET | 3445 | 2.44 |
03:38 ET | 6821 | 2.43 |
03:39 ET | 3743 | 2.43 |
03:41 ET | 5981 | 2.43 |
03:43 ET | 17179 | 2.435 |
03:45 ET | 32918 | 2.46 |
03:48 ET | 13280 | 2.44 |
03:50 ET | 26859 | 2.435 |
03:52 ET | 44023 | 2.465 |
03:54 ET | 19295 | 2.475 |
03:56 ET | 55116 | 2.48 |
03:57 ET | 37340 | 2.475 |
03:59 ET | 245785 | 2.47 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Nuvation Bio Inc | 826.9M | -1.2x | --- |
Oruka Therapeutics Inc | 835.4M | -4.0x | --- |
Perspective Therapeutics Inc | 826.7M | -8.8x | --- |
CARGO Therapeutics Inc | 848.8M | -5.3x | --- |
Arrivent Biopharma Inc | 789.6M | -9.5x | --- |
MBX Biosciences Inc | 780.1M | -16.5x | --- |
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $826.9M |
---|---|
Revenue (TTM) | $1.4M |
Shares Outstanding | 334.8M |
Nuvation Bio Inc does not pay a dividend. | |
Beta | 1.37 |
EPS | $-2.11 |
Book Value | $2.76 |
P/E Ratio | -1.2x |
Price/Sales (TTM) | 576.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -37,474.14% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.